Formoterol Turbuhaler

DRUG5 trials

Sponsors

AstraZeneca

Conditions

AsthmaCOPD Method EvaluationChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease Method Evaluation

Early Phase 1

Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler

CompletedNCT01257048

AstraZenecaChronic Obstructive Pulmonary Disease Method Evaluation, COPD Method Evaluation

Start: 2011-08-31End: 2012-06-30Updated: 2012-09-03

Phase 3

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients

CompletedNCT00206154

AstraZenecaChronic Obstructive Pulmonary Disease

Start: 2005-04-30End: 2006-12-31Target: 1500Updated: 2009-03-27

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

CompletedNCT00206167

AstraZenecaChronic Obstructive Pulmonary Disease

Start: 2005-04-30End: 2007-09-30Target: 1600Updated: 2009-03-27

A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD

CompletedNCT00419744

AstraZenecaChronic Obstructive Pulmonary Disease

Start: 2007-01-31End: 2009-08-31Updated: 2010-09-16

Phase 4

Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations

CompletedNCT00272753

AstraZenecaAsthma

Start: 2004-04-30End: 2005-11-30Target: 20Updated: 2011-06-01

Related Papers

Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials.

2018-01-10303 citations

Modelling peripheral blood eosinophils to identify response to budesonide in COPD: a post-hoc analysis

2017-09-011 citations

Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease.

2015-08-2133 citations

ADRB2 polymorphisms and budesonide/formoterol responses in COPD.

2012-08-0122 citations

Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.

2011-10-26110 citations

Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD.

2011-04-3023 citations

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.

2009-01-01152 citations

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.

2008-01-01148 citations